US › Healthcare

Enveric Biosciences Inc (ENVB)

US · Healthcare · Biotechnology

$1.69+5.62%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-1.6M
Profit YoY
+25.2%
EPS
$-1.08

Key statistics

Market cap
$6.3M
Forward P/E
23.1
P/B
1.25
Book value
$2.68
EPS (TTM)
$-22.74
52-week high
$17.64
52-week low
$1.25
50-day MA
$1.58
200-day MA
$3.44
Beta
1.14

Analyst view

Analysts rate Enveric Biosciences Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Shareholding

Insiders
10.81%
Institutions
2.93%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.80%
AdvisorShares Investments, LLC0.42%
UBS Group AG0.09%
Tower Research Capital LLC0.03%
JONES FINANCIAL COMPANIES LLLP0.02%
SBI Securities Co Ltd0.00%
BlackRock Inc0.00%
Wells Fargo & Co0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Enveric Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.